person · Reporting owner

Mendel Scott

Disclosed activity across 4 companies

Tapewire entity: 31180
SEC CIK: 0001515051

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GenMark Diagnostics, Inc.GNMK · Entity 140086	Director · President & CEO	April 22, 2021	April 22, 2021
Quanterix CorpQTRX · Entity 6649	Director	October 01, 2026	October 03, 2026
Quantum-Si IncQSI · Entity 6440	Director	May 18, 2026	May 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GenMark Diagnostics, Inc.

Report date April 22, 2021 · Filed April 22, 2021

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-04-22 transaction · row 1 1 source row Row 1 · 2021-04-22 · Other · Disposed 507,198 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F2: Includes 360,695 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU.
Common StockSEC Table I · non-derivative	IndirectMendel Trust dated October 14, 2011	Reported balance After 2021-04-22 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-04-22 · Other · Disposed 115,491 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F3: Mr. Mendel is the trustee of the Mendel Trust and has voting and dispositive power with respect to these shares. Mr. Mendel disclaims beneficial ownership except to the extent of his pecuniary interest therein.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-04-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-04-22 · Disposition to issuer · Disposed 28,332 · Balance 0 F4: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-04-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-04-22 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-04-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-04-22 · Disposition to issuer · Disposed 53,382 · Balance 0 F4: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.43 · Expires 2024-05-13	Direct	Reported balance After 2021-04-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-04-22 · Disposition to issuer · Disposed 84,002 · Balance 0 F5: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.17 · Expires 2025-02-19	Direct	Reported balance After 2021-04-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-04-22 · Disposition to issuer · Disposed 35,552 · Balance 0 F5: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

F2: Includes 360,695 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU.

F3: Mr. Mendel is the trustee of the Mendel Trust and has voting and dispositive power with respect to these shares. Mr. Mendel disclaims beneficial ownership except to the extent of his pecuniary interest therein.

F4: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU.

F5: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof.

Quanterix Corp

Report date October 01, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,454	Reported balance After 2026-10-01 transaction · row 1 1 source row Row 1 · 2026-10-01 · Grant · Acquired 4,398 · Balance 28,454 F1: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2026.

Quantum-Si Inc

Report date May 18, 2026 · Filed May 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2036-05-18	Direct	251,185	Reported balance After 2026-05-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-18 · Grant · Acquired 251,185 · Balance 251,185 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.
Class A Common StockSEC Table I · non-derivative	Direct	141,843	Reported balance Holding disclosure · report date 2026-05-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 141,843

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Akoya Biosciences, Inc.

Report date July 08, 2025 · Filed July 11, 2025

Section 16 reporting ended · disclosed 2025-07-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-07-08 transaction · row 1 1 source row Row 1 · 2025-07-08 · Other · Disposed 28,500 · Balance 0 F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.94 · Expires 2031-06-11	Direct	Reported balance After 2025-07-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-08 · Other · Disposed 35,562 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.24 · Expires 2032-06-01	Direct	Reported balance After 2025-07-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-08 · Other · Disposed 30,549 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2033-06-01	Direct	Reported balance After 2025-07-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-08 · Other · Disposed 56,322 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.68 · Expires 2034-10-02	Direct	Reported balance After 2025-07-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-08 · Other · Disposed 44,959 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2034-06-04	Direct	Reported balance After 2025-07-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-08 · Other · Disposed 50,000 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.

F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.

F3: Disposition of options pursuant to Merger Agreement.

F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 01, 2026 Filed Oct 3, 2026 00:02 UTC	Quanterix Corp QTRX · Entity 6649	GrantCommon Stock	4,398	$3.41	$14,997.18	Disclosure SEC source: 0001515051-26-000005 · primarydocument.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,454 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2026. Read SEC document
July 08, 2026 Filed Jul 9, 2026 21:20 UTC	Quanterix Corp QTRX · Entity 6649	Exercise / conversionRestricted Stock Unit · Derivative	8,073	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001515051-26-000004 · primarydocument.xml · derivative · entry 2 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,391 Underlying: Common Stock · 8,073 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On July 8, 2025, the reporting person was granted 24,464 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively. F2 · derivative.expiration_date: On July 8, 2025, the reporting person was granted 24,464 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively. Read SEC document
July 08, 2026 Filed Jul 9, 2026 21:20 UTC	Quanterix Corp QTRX · Entity 6649	Exercise / conversionCommon Stock	8,073	Not disclosed	Not disclosed	Disclosure SEC source: 0001515051-26-000004 · primarydocument.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
July 01, 2026 Filed Jul 2, 2026 20:03 UTC	Quanterix Corp QTRX · Entity 6649	GrantCommon Stock	3,456	$4.34	$14,999.04	Disclosure SEC source: 0001515051-26-000003 · primarydocument.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,837 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2026. Read SEC document
May 18, 2026 Filed May 20, 2026 20:05 UTC	Quantum-Si Inc QSI · Entity 6440	GrantStock Option (right to buy) · Derivative	251,185	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001140361-26-022242 · form4.xml · derivative · entry 2 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,185 Underlying: Class A Common Stock · 251,185 shares Expires 2036-05-18 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. Read SEC document
April 01, 2026 Filed Apr 7, 2026 11:24 UTC	Quanterix Corp QTRX · Entity 6649	GrantCommon Stock	4,310	$0.00	$0.00	Disclosure SEC source: 0001515051-26-000002 · primarydocument.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,527 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the first quarter of 2026. Read SEC document
January 02, 2026 Filed Jan 6, 2026 22:45 UTC	Quanterix Corp QTRX · Entity 6649	GrantCommon Stock	1,944	$0.00	$0.00	Disclosure SEC source: 0001515051-26-000001 · primarydocument.xml · nonDerivative · entry 2 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,053 F3 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2025. F2 · balance_after: Includes 47,836 restricted stock units. Read SEC document
January 02, 2026 Filed Jan 6, 2026 22:45 UTC	Quanterix Corp QTRX · Entity 6649	GrantCommon Stock	23,372	$0.00	$0.00	Disclosure SEC source: 0001515051-26-000001 · primarydocument.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,109 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on January 2, 2027 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 47,836 restricted stock units. Read SEC document
October 01, 2025 Filed Oct 4, 2025 00:53 UTC	Quanterix Corp QTRX · Entity 6649	GrantCommon Stock	2,084	$5.54	$11,545.36	Disclosure SEC source: 0001515051-25-000003 · primarydocument.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,737 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2025. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2025. F3 · balance_after: Includes 24,464 restricted stock units. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:39 UTC	Quanterix Corp QTRX · Entity 6649	GrantStock Option (right to buy) · Derivative	50,758	$0.00 Strike: $6.54	$0.00	Disclosure SEC source: 0001562180-25-005379 · primarydocument.xml · derivative · entry 3 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,758 Underlying: Common Stock · 50,578 shares Expires 2035-07-08 F4 · derivative.exercise_date: The option vests as to one-third of the shares on July 8, 2026, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:39 UTC	Quanterix Corp QTRX · Entity 6649	GrantCommon Stock	24,464	$0.00	$0.00	Disclosure SEC source: 0001562180-25-005379 · primarydocument.xml · nonDerivative · entry 2 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,653 F2 · shares: Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of the shares on each of July 8, 2026, July 8, 2027 and July 8, 2028. F3 · balance_after: Includes 24,464 restricted stock units. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:39 UTC	Quanterix Corp QTRX · Entity 6649	GrantCommon Stock	4,189	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-25-005379 · primarydocument.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,189 F1 · price: Received in exchange for 28,500 shares of Akoya Biosciences, Inc. ("Akoya") common stock in connection with the acquisition of Akoya by Quanterix on July 8, 2025. Mr. Mendel received: (a) 0.1470 of a share of Quanterix common stock and (b) $0.37 in cash, for each share of Akoya common stock. The closing price of the Quanterix common stock on July 8, 2025 was $6.54 per share. The closing price of the Akoya common stock on July 7, 2025 was $1.29 per share. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:41 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	OtherStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $2.01	$0.00	Disclosure SEC source: 0001062993-25-012732 · form4.xml · derivative · entry 6 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2034-06-04 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:41 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	OtherStock Option (right to buy) · Derivative	44,959	$0.00 Strike: $2.68	$0.00	Disclosure SEC source: 0001062993-25-012732 · form4.xml · derivative · entry 5 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,959 shares Expires 2034-10-02 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:41 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	OtherStock Option (right to buy) · Derivative	56,322	$0.00 Strike: $5.70	$0.00	Disclosure SEC source: 0001062993-25-012732 · form4.xml · derivative · entry 4 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,322 shares Expires 2033-06-01 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:41 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	OtherStock Option (right to buy) · Derivative	30,549	$0.00 Strike: $11.24	$0.00	Disclosure SEC source: 0001062993-25-012732 · form4.xml · derivative · entry 3 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,549 shares Expires 2032-06-01 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:41 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	OtherStock Option (right to buy) · Derivative	35,562	$0.00 Strike: $19.94	$0.00	Disclosure SEC source: 0001062993-25-012732 · form4.xml · derivative · entry 2 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,562 shares Expires 2031-06-11 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document
July 08, 2025 Filed Jul 11, 2025 00:41 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	OtherCommon Stock	28,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-25-012732 · form4.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2 · shares: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. F2 · price: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. Read SEC document
May 19, 2025 Filed May 21, 2025 20:01 UTC	Quantum-Si Inc QSI · Entity 6440	GrantStock Option (right to buy) · Derivative	126,095	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001140361-25-020041 · form4.xml · derivative · entry 2 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,095 Underlying: Class A Common Stock · 126,095 shares Expires 2035-05-19 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. Read SEC document
October 02, 2024 Filed Oct 4, 2024 22:44 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	GrantStock Option (right to buy) · Derivative	44,959	$0.00 Strike: $2.68	$0.00	Disclosure SEC source: 0001062993-24-017438 · form4.xml · derivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,959 Underlying: Common Stock · 44,959 shares Expires 2034-10-02 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting dates, the options shall vest ratably on a quarterly basis over four quarters, with the first vesting date to occur on January 1, 2025. Read SEC document
June 04, 2024 Filed Jun 5, 2024 21:53 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $2.01	$0.00	Disclosure SEC source: 0001104659-24-068745 · tm2416554-1_4seq1.xml · derivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 4, 2025, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document
May 16, 2024 Filed May 17, 2024 20:47 UTC	Quantum-Si Inc QSI · Entity 6440	GrantStock Option (right to buy) · Derivative	113,281	$0.00 Strike: $1.86	$0.00	Disclosure SEC source: 0001140361-24-026712 · form4.xml · derivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,281 Underlying: Class A Common Stock · 113,281 shares Expires 2034-05-16 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Mendel's continued service through the applicable vesting date. Read SEC document
June 12, 2023 Filed Jun 12, 2023 22:17 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	PurchaseCommon Stock	20,000	$5.00	$100,000.00	Disclosure SEC source: 0001104659-23-070483 · tm2318472-4_4seq1.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Read SEC document
June 01, 2023 Filed Jun 5, 2023 21:38 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	GrantStock Option (Right to Buy) · Derivative	56,322	$0.00 Strike: $5.70	$0.00	Disclosure SEC source: 0001104659-23-068153 · tm2317841-5_4seq1.xml · derivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,322 Underlying: Common Stock · 56,322 shares Expires 2033-06-01 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document
May 12, 2023 Filed May 16, 2023 20:53 UTC	Quantum-Si Inc QSI · Entity 6440	GrantClass A Common Stock	141,843	$0.00	$0.00	Disclosure SEC source: 0001140361-23-025054 · form4.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,843 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on May 12, 2024, subject to Mr. Mendel's continued service through the applicable vesting date. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:03 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	GrantStock Option (Right to Buy · Derivative	30,549	$0.00 Strike: $11.24	$0.00	Disclosure SEC source: 0001104659-22-068066 · tm2217652-2_4seq1.xml · derivative · entry 2 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,549 Underlying: Common Stock · 30,549 shares Expires 2032-06-01 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document
November 19, 2021 Filed Nov 19, 2021 17:55 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	PurchaseCommon Stock	8,500	$13.16	$111,860.00	Disclosure SEC source: 0001104659-21-141727 · tm2133536-1_4seq.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Read SEC document
June 11, 2021 Filed Jun 16, 2021 01:59 UTC	Akoya Biosciences, Inc. AKYA · Entity 77553	GrantStock Option (Right to Buy · Derivative	35,562	$0.00 Strike: $19.94	$0.00	Disclosure SEC source: 0001104659-21-081691 · tm2119879-1_4seq1.xml · derivative · entry 1 Mendel Scott · CIK 0001515051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,562 Underlying: Common Stock · 36,562 shares Expires 2031-06-11 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in three (3) equal installments beginning on June 11, 2022 and annually thereafter until fully vested. Read SEC document
April 22, 2021 Filed Apr 22, 2021 13:49 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Disposition to issuerStock Option (Right to Buy) · Derivative	35,552	Not disclosed Strike: $13.17	Not disclosed	Disclosure SEC source: 0001487371-21-000166 · wf-form4_161911375108704.xml · derivative · entry 7 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,552 shares Expires 2025-02-19 F5 · price: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof. Read SEC document
April 22, 2021 Filed Apr 22, 2021 13:49 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Disposition to issuerStock Option (Right to Buy) · Derivative	84,002	Not disclosed Strike: $9.43	Not disclosed	Disclosure SEC source: 0001487371-21-000166 · wf-form4_161911375108704.xml · derivative · entry 6 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,002 shares Expires 2024-05-13 F5 · price: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof. Read SEC document
April 22, 2021 Filed Apr 22, 2021 13:49 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Disposition to issuerMarket Stock Units · Derivative	53,382	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001487371-21-000166 · wf-form4_161911375108704.xml · derivative · entry 5 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,382 shares Expires not disclosed F4 · price: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. F4 · derivative.exercise_date: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. F4 · derivative.expiration_date: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. Read SEC document
April 22, 2021 Filed Apr 22, 2021 13:49 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Disposition to issuerMarket Stock Units · Derivative	100,000	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001487371-21-000166 · wf-form4_161911375108704.xml · derivative · entry 4 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F4 · price: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. F4 · derivative.exercise_date: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. F4 · derivative.expiration_date: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. Read SEC document
April 22, 2021 Filed Apr 22, 2021 13:49 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Disposition to issuerMarket Stock Units · Derivative	28,332	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001487371-21-000166 · wf-form4_161911375108704.xml · derivative · entry 3 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,332 shares Expires not disclosed F4 · price: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. F4 · derivative.exercise_date: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. F4 · derivative.expiration_date: The Merger Agreement provides that (i) each unvested MSU awarded pursuant to any Company Plan that is outstanding immediately prior to the Merger Effective Time will automatically fully vest (based on the performance level attained pursuant to the terms of the applicable award agreement, including any provision therein related to the effect of a change of control) and become a vested MSU in accordance with its terms and (ii) each MSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any vested MSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such vested MSU. Read SEC document
April 22, 2021 Filed Apr 22, 2021 13:49 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	OtherCommon Stock	115,491	$24.05	$2,777,558.55	Disclosure SEC source: 0001487371-21-000166 · wf-form4_161911375108704.xml · nonDerivative · entry 2 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Mendel Trust dated October 14, 2011 Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F3 · ownership.nature: Mr. Mendel is the trustee of the Mendel Trust and has voting and dispositive power with respect to these shares. Mr. Mendel disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document
April 22, 2021 Filed Apr 22, 2021 13:49 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	OtherCommon Stock	507,198	$24.05	$12,198,111.90	Disclosure SEC source: 0001487371-21-000166 · wf-form4_161911375108704.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F2 · shares: Includes 360,695 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU. Read SEC document
February 25, 2021 Filed Mar 1, 2021 17:53 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Tax withholdingCommon Stock	41,834	$0.00	$0.00	Disclosure SEC source: 0001487371-21-000130 · wf-form4_161463917738390.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,198 Read SEC document
February 23, 2021 Filed Feb 25, 2021 18:33 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Tax withholdingCommon Stock	3,254	$0.00	$0.00	Disclosure SEC source: 0001487371-21-000110 · wf-form4_161429595806893.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,032 Read SEC document
February 22, 2021 Filed Feb 24, 2021 18:05 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Tax withholdingCommon Stock	1,860	$0.00	$0.00	Disclosure SEC source: 0001487371-21-000086 · wf-form4_161420789541215.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,286 Read SEC document
February 18, 2021 Filed Feb 22, 2021 18:59 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	GrantMarket Stock Units · Derivative	26,691	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001487371-21-000066 · wf-form4_161403836097606.xml · derivative · entry 4 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,691 Underlying: Common Stock · 26,691 shares Expires not disclosed F3 · shares: Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index. F4 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2021, December 31, 2022, and December 31, 2023; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. F4 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2021, December 31, 2022, and December 31, 2023; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Read SEC document
February 18, 2021 Filed Feb 22, 2021 18:59 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	GrantCommon Stock	80,070	$0.00	$0.00	Disclosure SEC source: 0001487371-21-000066 · wf-form4_161403836097606.xml · nonDerivative · entry 2 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,146 F1 · kind: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2020 Equity Incentive Plan. The restricted stock units vest 25% on February 18, 2022 and the remaining shares subject to such award vest in 12 equal quarterly installments thereafter. Read SEC document
February 18, 2021 Filed Feb 22, 2021 18:59 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Tax withholdingCommon Stock	3,952	$0.00	$0.00	Disclosure SEC source: 0001487371-21-000066 · wf-form4_161403836097606.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,076 Read SEC document
January 25, 2021 Filed Jan 25, 2021 20:35 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	64,975	$14.23	$924,594.25	Disclosure SEC source: 0001487371-21-000019 · wf-form4_161162490273762.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,028 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document
January 21, 2021 Filed Jan 21, 2021 20:09 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionMarket Stock Units · Derivative	50,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001487371-21-000007 · wf-form4_161127777816658.xml · derivative · entry 8 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's one-year total Shareholder return, as compared to the Nasdaq Composite Index. F7 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2020, December 31, 2021, and December 31, 2022; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's one-year total Shareholder return, as compared to the Nasdaq Composite Index. F6 · balance_after: Represents the target number of shares which remain subject to the award. Read SEC document
January 21, 2021 Filed Jan 21, 2021 20:09 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionMarket Stock Units · Derivative	46,098	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001487371-21-000007 · wf-form4_161127777816658.xml · derivative · entry 7 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,167 Underlying: Common Stock · 46,098 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's two-year total Shareholder return, as compared to the Nasdaq Composite Index. F5 · derivative.expiration_date: The MSUs vest in three equal installments, on each of December 31, 2019, December 31, 2020, and December 31, 2021; provided that, at the end of the second and third performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the NASDAQ Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's two-year total Shareholder return, as compared to the Nasdaq Composite Index. F6 · balance_after: Represents the target number of shares which remain subject to the award. Read SEC document
January 21, 2021 Filed Jan 21, 2021 20:09 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionMarket Stock Units · Derivative	50,074	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001487371-21-000007 · wf-form4_161127777816658.xml · derivative · entry 6 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,074 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The MSUs vested in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person was eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's three-year total Shareholder return, as compared to the Nasdaq Composite Index. F4 · derivative.expiration_date: The MSUs vested in three equal installments, on each of December 31, 2018, December 31, 2019, and December 31, 2020; provided that, at the end of the second and third annual performance periods, the Reporting Person was eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index. Based on actual performance, the Reporting Person was issued the maximum number of shares based on the Issuer's three-year total Shareholder return, as compared to the Nasdaq Composite Index. Read SEC document
January 21, 2021 Filed Jan 21, 2021 20:09 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001487371-21-000007 · wf-form4_161127777816658.xml · nonDerivative · entry 5 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 21, 2021 Filed Jan 21, 2021 20:09 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionCommon Stock	46,098	$0.00	$0.00	Disclosure SEC source: 0001487371-21-000007 · wf-form4_161127777816658.xml · nonDerivative · entry 4 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 21, 2021 Filed Jan 21, 2021 20:09 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	Exercise / conversionCommon Stock	50,074	$0.00	$0.00	Disclosure SEC source: 0001487371-21-000007 · wf-form4_161127777816658.xml · nonDerivative · entry 3 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 19, 2021 Filed Jan 21, 2021 20:09 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	50,000	$14.54	$727,000.00	Disclosure SEC source: 0001487371-21-000007 · wf-form4_161127777816658.xml · nonDerivative · entry 2 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Mendel Trust dated October 14, 2011 Disclosed balance after: 115,491 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by reporting person in July 2020. F2 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $14.09 to $14.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. F3 · ownership.nature: Mr. Mendel is the trustee of the Mendel Trust and has voting and dispositive power with respect to these shares. Mr. Mendel disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document
November 24, 2020 Filed Nov 25, 2020 17:29 UTC	GenMark Diagnostics, Inc. GNMK · Entity 140086	SaleCommon Stock	5,190	$13.17	$68,352.30	Disclosure SEC source: 0001487371-20-000366 · wf-form4_160634338470711.xml · nonDerivative · entry 1 Mendel Scott · CIK 0001515051 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,830 F1 · kind: The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.